Literature DB >> 8673052

Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.

K Y Chiang1, D J Weisdorf, S M Davies, H Enright, J H Kersey, P B McGlave, W Miller, N K Ramsay, M Steinbuch, J E Wagner, B R Blazar.   

Abstract

Twenty-three second bone marrow transplants (BMT) were performed between October 1987 and January 1994 for patients with malignant relapse following initial BMT. For first BMT, twenty-one of 23 (91%) were conditioned with cyclophosphamide plus total body irradiation. For second BMT, a uniform conditioning regimen consisting of busulfan and cyclophosphamide was used. Eleven patients had chronic myelogenous leukemia, seven acute leukemia, four lymphoma, and one myelodysplastic syndrome. Median patient age at second BMT was 32 years, the median time between first BMT and relapse was 22 months, and the median time to second BMT after relapse was 5 months. The second BMT marrow source included: autologous marrow (1), unrelated donors (4), new matched sibling donors (5) and same matched sibling donors as the first BMT (13). The Kaplan-Meier disease-free survival and survival rates at 3 years were 38 and 43%, respectively (median follow-up of survivors was 45 and 48 months, respectively), and five patients survive disease-free at 4-6 years. Nine of the 13 deaths occurred within 100 days after second BMT; eight had relapsed within 1 year of the first BMT. We conclude that: (1) second BMT can offer durable long-term survival in certain patients, especially those who relapse late after first transplant; (2) busulfan and cyclophosphamide is a suitable conditioning regimen for second BMT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673052

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).

Authors:  Asad Bashey; Kouros Owzar; Jeffrey L Johnson; Peggy S Edwards; Michael Kelly; Lee-Ann Baxter-Lowe; Steven Devine; Sherif Farag; David Hurd; Edward Ball; Philip McCarthy; John Lister; Thomas C Shea; Charles Linker
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

Review 2.  The role of second transplants for leukemia.

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-19       Impact factor: 3.020

3.  Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.

Authors:  N Kono; K Ohashi; E Sasaki; Y Okoshi; D Mizuchi; S Mori; H Akiyama; K Karasawa; H Kaku; R Okamoto; Y Maeda; T Sasaki; Y Okuyama; K Hiruma; H Sakamaki
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

4.  Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.

Authors:  Akira Tomonari; Tohru Iseki; Jun Ooi; Hitomi Nagayama; Hiroyuki Sato; Tsutomu Takahashi; Kiyoshi Ito; Fumitaka Nagamura; Kaoru Uchimaru; Satoshi Takahashi; Naoki Shirafuji; Arinobu Tojo; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

5.  Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity.

Authors:  Toshihiko Ando; Noriyuki Mitani; Kumiko Matsui; Koji Yamashita; Jun Nomiyama; Masatoshi Tsuru; Toshiaki Yujiri; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

6.  Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.

Authors:  James M Foran; Steven Z Pavletic; Brent R Logan; Manza A Agovi-Johnson; Waleska S Pérez; Brian J Bolwell; Martin Bornhäuser; Christopher N Bredeson; Mitchell S Cairo; Bruce M Camitta; Edward A Copelan; Jason Dehn; Robert P Gale; Biju George; Vikas Gupta; Gregory A Hale; Hillard M Lazarus; Mark R Litzow; Dipnarine Maharaj; David I Marks; Rodrigo Martino; Richard T Maziarz; Jacob M Rowe; Philip A Rowlings; Bipin N Savani; Mary Lynn Savoie; Jeffrey Szer; Edmund K Waller; Peter H Wiernik; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-28       Impact factor: 5.742

Review 7.  Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 8.  Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant.

Authors:  Koen van Besien; Sonali Smith; Hillard M Lazarus
Journal:  Curr Treat Options Oncol       Date:  2005-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.